Clinical trials: Stage III Renal Cell Cancer AJCC v8
Kidney Cancer
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Interferon alfa-2b may interfere with the growth of the cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00005966
- Testing
- recombinant interferon alfa, thalidomide
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Kidney Cancer
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have…
- Trial name
- NCT00005027
- Testing
- becatecarin
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to…
- Conditions
- Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04393350
- Testing
- Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer…
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- PROBE (NCT04510597)
- Testing
- Cytoreductive Nephrectomy, Active Comparator
- Where
- 387 sites in United States
- Volunteers
- 364 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa in treating patients with advanced kidney cancer.
- Trial name
- NCT00003542
- Testing
- pegylated interferon alfa
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
- Trial name
- NCT00005816
- Testing
- therapeutic autologous dendritic cells, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell kidney (renal cell) cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT07226544
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Kidney Cancer
MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
RATIONALE: Comparing results of MRI scans done after bevacizumab may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00873236
- Testing
- bevacizumab, recombinant interferon alpha-2a
- Where
- 5 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients…
- Conditions
- Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- NCT03055013
- Testing
- Nephrectomy, Nivolumab, Patient Observation
- Where
- 413 sites in United States, Canada and 1 more
- Volunteers
- 819 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05361720
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324740
- Testing
- vorinostat, isotretinoin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with bevacizumab and to see how well they work in treating patients with unresectable or metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324870
- Testing
- vorinostat, bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable…
- Trial name
- NCT00016939
- Testing
- alvocidib
- Where
- 101 sites in United States
- Sponsor
- SWOG Cancer Research Network